Role of microbiota in Crohn's disease induction in the light of studies of Human Microbiome Project;Rola mikroflory jelit w indukcji choroby leśniewskiego-Crohna w świetle programu badań Human Microbiome Project

Postepy Mikrobiologii

Volumn 51, Issue 4, 2012, Pages 257-264

  Franczuk, Artur ^a   Jagusztyn Krynicka, Elzbieta Katarzyna ^a  

^a UNIVERSITY OF WARSAW   (Poland)

Author keywords

Comensals; Crohn's disease; Dysbiosis; HMP; Inflammation; Metagenomics; Microbiota

Indexed keywords

CROHN DISEASE; GENETIC PREDISPOSITION; IMMUNE SYSTEM; INFLAMMATION; MICROFLORA; REVIEW;

EID: 84873864405     PISSN: 00794252     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Abubakar I., Myhill D., Aliyu S.H., Hunter, P. R.: Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm. Bowel Dis. 14, 401-410 (2008)
2. Andoh A., Imaeda H., Aomatsu T., Inatomi O., Bamba S., Sasaki M., Saito Y., Tsujikawa T., Fujiyama Y.: Comparison of the fecal microbiota profiles between ulcerative colitis and Crohn's disease using terminal restriction fragment length polymorphism analysis. J. Gastroenterol. 46, 479-486 (2011)
3. Barcenilla A., Pryde S.E., Martin J.C., Duncan S.H., Stewart C.S., Henderson C., Flint H.J.: Phylogenetic relationships of butyrate-producing bacteria from the human gut. Appl. Environ. Microbiol. 66, 1654-1661 (2000)
4. Baumgart M., K.W. Simpson i wsp.: Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. Isme J. 1, 403-418 (2007)
5. Boudeau J., Glasser A.L., Masseret E., Joly B., Darfeuille-Michaud A.: Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect. Immun. 67, 4499-4509 (1999)
6. Bringer M.A., Glasser A.L., Tung C.H., Meresse S., Darfeuille-Michaud A.: The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell Microbiol. 8, 471-484 (2006)
7. Campos N., Sarmento A. i wsp.: Macrophages from IBD patients exhibit defective tumour necrosis factor-alpha secretion but otherwise normal or augmented pro-inflammatory responses to infection. Immunobiology, 216, 961-970 (2011)
8. Chen W., Li D., Wilson I., Chadwick V.S.: Detection of Chlamydia pneumoniae by polymerase chain reaction-enzyme immunoassay in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. J. Gastroenterol. Hepatol. 17, 987-993 (2002)
9. Dicksved J., Halfvarson J., Rosenquist M., Järnerot G., Tysk C., Apajalahti J., Engstrand L., Jansson J.K.: Molecular analysis of the gut microbiota of identical twins with Crohn's disease. Isme J. 2, 716-727 (2008)
10. Eckburg P.B., Bik E.M., Bernstein C.N., Purdom E., Dethlefsen L., Sargent M., Gill S.R., Nelson K.E., Relman D.A.: Diversity of the human intestinal microbial flora. Science, 308, 1635-1638 (2005)
11. Fava F., Danese, S.: Intestinal microbiota in inflammatory bowel disease: Friend of foe? World J. Gastroenterol. 17, 557-566 (2011)
12. Frank D.N., St Amand A.L., Feldman R.A., Boedeker E.C., Harpaz N., Pace N.R.: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. USA, 104, 13780-13785 (2007)
13. Franke A., M. Parkes i wsp.: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118-1125 (2010)
14. Fujimura Y., Kamoi R., Iida M.: Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut, 38, 724-732 (1996)
15. Gassler N., Rohr C., Schneider A., Kartenbeck J., Bach A., Obermüller N., Otto H.F., Autschbach F.: Inflammatory bowel disease is associated with changes of enterocytic junctions. Am. J. Physiol. Gastrointest. Liver Physiol. 281, 216-228 (2001)
16. Handelsman J., Rondon M.R., Brady S.F., Clardy J., Goodman R.M.: Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. Chem. Biol. 5, 245-249 (1998)
17. Hugot J.P., Thomas G. i wsp.: Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 411, 599-603 (2001)
18. Hugot J.P., Parkes M. i wsp.: Prevalence of CARD15/NOD2 mutations in Caucasian healthy people. Am. J. Gastroenterol. 102, 1259-1267 (2007)
19. Inohara N., Nunez G.: NODs: intracellular proteins involved in inflammation and apoptosis. Nat. Rev. Immunol. 3, 371-382 (2003)
20. Inohara N., Ogura Y., Chen F.F., Muto A., Nunez G.: Human Nod1 confers responsiveness to bacterial lipopolysaccharides. J. Biol. Chem. 276, 2551-2554 (2001)
21. Isbister W.H.: Colonoscopy: how far is enough? Aust. N.Z.J. Surg. 65, 44-47 (1995)
22. Joossens M., Huys G., Cnockaert M., De Preter V., Verbeke K., Rutgeerts P., Vandamme P., Vermeire S.: Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut, 60, 631-637 (2011)
23. Kobayashi K.S., Chamaillard M., Ogura Y., Henegariu O., Inohara N., Nuñez G., Flavell R.A.:Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science, 307, 731-734 (2005)
24. Kosovac K., Brenmoehl J., Holler E., Falk W., Schoelmerich J., Hausmann M., Rogler G.: Association of the NOD2 genotype with bacterial translocation via altered cell-cell contacts in Crohn's disease patients. Inflamm. Bowel Dis. 16, 1311-1321 (2010)
25. Kotlowski R., Bernstein C.N., Sepehri S., Krause D.O.: High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut, 56, 669-675 (2007)
26. Liu Y, van Kruiningen H.J., West A.B., Cartun R.W., Cortot A., Colombel J.F.: Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease. Gastroenterology, 108, 1396-1404 (1995)
27. Mangin, Doré J. i wsp.: Molecular inventory of faecal microflora in patients with Crohn's disease. FEMS Microbiol. Ecol. 50, 25-36 (2004)
28. Manichanh C., Doré J. i wsp.: Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut, 55, 205-211 (2006)
29. Martin H.M., Campbell B.J., Hart C.A., Mpofu C., Nayar M., Singh R., Englyst H., Williams H.F., Rhodes J.M.: Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology, 127, 80-93 (2004)
30. Maśliński S., Ryżewski J., Patofizjologia dia studentów medycyny. Wydawnictwo lekarskie PZWL, Warszawa, 1998 s. 733-739 i 777
31. McCann K. S. The diversity-stability debate. Nature, 405, 228-233 (2000).
32. McGuckin M.A., Eri R., Simms L.A., Florin T.H., Radford-Smith G.: Intestinal barrier dysfunction in inflammatory bowel diseases. Inflamm. Bowel Dis. 15, 100-113 (2009)
33. Miquel S., Darfeuille-Michaud A. i wsp.: Complete genome sequence of Crohn's disease-associated adherent-invasive E. coli strain LF82. PLoS One, 5, 12714 (2010)
34. Naser S.A., Hulten K., Shafran I., Graham D.Y., El-Zaatari F.A.: Specific seroreactivity of Crohn's disease patients against p35 and p36 antigens of M. avium subsp. paratuberculosis. Vet. Microbiol. 77, 497-504 (2000)
35. Nuding S., Fellermann K., Wehkamp J., Stange E.F.: Reduced mucosal antimicrobial activity in Crohn's disease of the colon. Gut, 56, 1240-1247 (2007)
36. Ott S.J., Musfeldt M., Wenderoth D.F., Hampe J., Brant O., Fölsch U.R., Timmis K.N., Schreiber S.: Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut, 53, 685-693 (2004)
37. Peterson D.A., Frank D.N., Pace N.R., Gordon J.I.: Metagenomic approaches for defining the pathogenesis of inflammatory bowel diseases. Cell. Host. Microbe, 3, 417-427 (2008)
38. Rabizadeh S., Rhee K.J., Wu S., Huso D., Gan C.M., Golub J.E., Wu X., Zhang M., Sears C.L.: Enterotoxigenic Bacteroides fragilis: a potential instigator of colitis. Inflamm. Bowel Dis. 13, 1475-1483 (2007)
39. Resnick R.H., Royal H., Marshall W., Barron R., Werth T.: Intestinal permeability in gastrointestinal disorders. Use of oral [99mTc]DTPA. Dig. Dis. Sci. 35, 205-211 (1990)
40. Rhodes J.M.: The role of Escherichia coli in inflammatory bowel disease. Gut, 56, 610-612 (2007)
41. Roediger W. E.: The colonic epithelium in ulcerative colitis: an energy-deficiency disease? Lancet, 2, 712-715 (1980)
42. Rolhion N., Hofman P., Darfeuille-Michaud A.: The endoplasmic reticulum stress response chaperone: Gp96, a host receptor for Crohn disease-associated adherent-invasive Escherichia coli. Gut Microbes. 2, 115-119 (2011)
43. Scanlan P.D., Shanahan F., O'Mahony C., Marchesi J.R.: Culture-independent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J. Clin. Microbiol. 44, 3980-3988 (2006)
44. Schmitz H., Fromm M., Bentzel C.J., Scholz P., Detjen K., Mankertz J., Bode H., Epple H.J., Riecken E.O., Schulzke J.D.: Tumor necrosis factor-alpha (TNFalpha) regulates the epithelial barrier in the human intestinal cell line HT-29/B6. J. Cell Sci. 112, 137-146 (1999)
45. Segain J.P., Raingeard de la Blétière D., Bourreille A., Leray V., Gervois N., Rosales C., Ferrier L., Bonnet C., Blottière H.M., Galmiche J.P.: Butyrate inhibits inflammatory responses through NFκB inhibition: implications for Crohn's disease. Gut, 47, 397-403 (2000)
46. Sepehri S., Khafipour E., Bernstein C.N., Coombes B.K., Pilar A.V., Karmali M., Ziebell K., Krause D.O.: Characterization of Escherichia coli isolated from gut biopsies of newly diagnosed patients with inflammatory bowel disease. Inflamm. Bowel Dis. 17, 1451-1463 (2011)
47. Sepehri S., Kotlowski R., Bernstein C.N., Krause D.O.: Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm. Bowel Dis. 13, 675-683 (2007)
48. Sitaraman S.V., Klapproth J.M., Moore D.A., Landers C., Targan S., Williams I.R., Gewirtz A.T.: Elevated flagellin-specific immunoglobulins in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288, 403-406 (2005)
49. Sokol H., P. Langella i wsp.: Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA, 105, 16731-16736 (2008)
50. Sperandio B., Regnault B., Guo J., Zhang Z., Stanley S.L. Jr, Sansonetti P.J., Pédron T.J.: Virulent Shigella flexneri subverts the host innate immune response through manipulation of antimicrobial peptide gene expression. Exp. Med. 205, 1121-1132 (2008)
51. Strober W., Fuss I., Mannon P.: The fundamental basis of inflammatory bowel disease. J. Clin. Invest. 117, 514-521 (2007)
52. Swidsinski A., Lochs H. i wsp.: Mucosal flora in inflammatory bowel disease. Gastroenterology 122, 44-54 (2002)
53. Swidsinski A., Loening-Baucke V., Lochs H., Hale L.P.: Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World J. Gastroenterol. 11, 1131-1140 (2005)
54. Swidsinski A., Loening-Baucke V., Vaneechoutte M., Doerffel Y.: Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. Inflamm. Bowel Dis. 14, 147-161 (2008)
55. Swidsinski A., Weber J., Loening-Baucke V., Hale L.P., Lochs H.: Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43, 3380-3389 (2005)
56. Takaishi H., Hibi T. i wsp.: Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int. J. Med. Microbiol. 298, 463-472 (2008)
57. Tamboli C.P., Neut C., Desreumaux P., Colombel J.F.: Dysbiosis in inflammatory bowel disease. Gut, 53, 1-4 (2004)
58. Thomas G.A., Swift G.L., Green J.T., Newcombe R.G., Braniff-Mathews C., Rhodes J., Wilkinson S., Strohmeyer G., Kreuzpainter G.: Controlled trial of antituberculous chemotherapy in Crohn's disease: a five year follow up study. Gut, 42, 497-500 (1998)
59. Uehara A., Yang S., Fujimoto Y, Fukase K., Kusumoto S., Shibata K., Sugawara S., Takada H.: Muramyldipeptide and diaminopimelic acid-containing desmuramylpeptides in combination with chemically synthesized Toll-like receptor agonists synergistically induced production of interleukin-8 in a NOD2- and NOD1-dependent manner, respectively, in human monocytic cells in culture. Cell Microbiol. 7, 53-61 (2005)
60. Vanhoutvin S.A., Troost F.J., Hamer H.M., Lindsey P.J., Koek G.H., Jonkers D.M., Kodde A., Venema K., Brummer R.J.: Butyrate-induced transcriptional changes in human colonic mucosa. PLoS One, 4, 6759 (2009)
61. Vejborg R.M., Hancock V., Petersen A.M., Krogfelt K.A., Klemm P.: Comparative genomics of Escherichia coli isolated from patients with inflammatory bowel disease. BMC Genomics, 12, 316 (2011)
62. Vermeire S.: NOD2/CARD15: relevance in clinical practice. Best Pract. Res. Clin. Gastroenterol. 18, 569-575 (2004)
63. Walker A.W., Sanderson J.D., Churcher C., Parkes G.C., Hudspith B.N., Rayment N., Brostoff J., Parkhill J., Dougan G., Petrovska L.: High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11, 7 (2011)
64. Wehkamp J., Stange E.F., Fellermann K.: Defensin-immunology in inflammatory bowel disease. Gastroenterol. Clin. Biol. 33 Suppl 3, 137-144 (2009)
65. Żyłowska M., Wyszyńska A., Jagusztyn-Krynicka E.K.: Defensyny - peptydy o aktywności przeciwbakteryjnej. Post. Mikrobiol. 50, 223-234 (2011)